Suomi - suomi - Fimea (Suomen lääkevirasto)

schaper & brummer gmbh & co.kg - echinacea purpurea root,echinacea kalpea root,tuija occididentalis kasvi,baptisia tinctoria root - tabletti - muut vilustumislÄÄkkeet

Euroopan unioni - suomi - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiset aineet - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. potilaat, joilla on alhainen tai hyvin alhainen riski toistumisen pitäisi saada adjuvanttihoitona. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. paitsi äskettäin diagnosoitu kroonisen vaiheen kml, ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia.

Suomi - suomi - Fimea (Suomen lääkevirasto)

w.f.young incorporated - tinctura artemisia,thujonum,chloroxylenolum,thujyl alcohol,mentholum,tanaceti aetheroleum,cedri ligni aetheroleum,iodum,absinthii aetheroleum,thymolum,safrolum - linimentti - muut

Euroopan unioni - suomi - EMA (European Medicines Agency)

krka, d.d. - memantiinihydrokloridia - alzheimerin tauti - muut dementia-lääkkeet - alzheimerin taudin keskivaikean tai vaikean potilaan hoito.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - memantiinihydrokloridia - alzheimerin tauti - muut dementia-lääkkeet - alzheimerin taudin keskivaikean tai vaikean potilaan hoito.

Euroopan unioni - suomi - EMA (European Medicines Agency)

ratiopharm gmbh - memantiinihydrokloridia - alzheimerin tauti - psychoanaleptics, - alzheimerin taudin keskivaikean tai vaikean potilaan hoito.

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva b.v. - salmeterol fluticasone propionate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - airexar spiromax on tarkoitettu käytettäväksi vain 18-vuotiailla ja sitä vanhemmilla aikuisilla. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. krooninen obstruktiivinen keuhkosairaus (copd)airexar spiromax on tarkoitettu oireenmukaiseen hoitoon potilailla, joilla on copd, fev1.

Euroopan unioni - suomi - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - rokotteet - infanrix penta on tarkoitettu pikkulasten primääri- ja tehosterokotuksia vastaan ​​kurkkumätä, tetanus, hinkuyskä, hepatiitti b ja poliomyeliitti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

viatris limited - tadalafil - hypertensio, keuhkokuume - urologiset - talmanco on tarkoitettu aikuisille keuhkoverenpainetaudin (pah) hoitoon, joka on luokiteltu who: n funktionaaliseksi luokaksi ii ja iii,. tehoa on osoitettu idiopaattisessa pah: ssa (ipah) ja pah: ssa, joka liittyy kollageenin verisuonisairauteen.

Euroopan unioni - suomi - EMA (European Medicines Agency)

astellas pharma europe bv - takrolimuusi - graft hylkääminen - immunosuppressantit - aivojen munuaisten tai maksan allograftin vastaanottajien profylaksi. allograftin hylkimisen hoito, joka on resistentti hoidossa muiden immunosuppressiivisten lääkevalmisteiden kanssa aikuisilla potilailla.